Vertex Historical Financial Ratios

VRTX Stock

USD 464.56 2.51 0.54%

Vertex Pharmaceuticals is promptly reporting on over 112 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0, PTB Ratio of 7.46 or Days Sales Outstanding of 58.28 will help investors to properly organize and evaluate Vertex Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

About Vertex Financial Ratios Analysis

Vertex PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Vertex Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Vertex financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Vertex Pharmaceuticals history.

Vertex Pharmaceuticals Financial Ratios Chart

At this time, Vertex Pharmaceuticals' Sales General And Administrative To Revenue is fairly stable compared to the past year. Cash Per Share is likely to rise to 45.71 in 2024, whereas Price To Sales Ratio is likely to drop 10.09 in 2024.

Days Sales Outstanding Book Value Per Share Free Cash Flow Yield Invested Capital Days Of Inventory Outstanding

Add Fundamental

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Invested Capital

Invested capital represents the total cash investment that shareholders and debt holders have contributed to Vertex Pharmaceuticals. There are two different methods for calculating Vertex Pharmaceuticals invested capital: operating approach and financing approach. Understanding Vertex Pharmaceuticals invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.

Most ratios from Vertex Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Vertex Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.At this time, Vertex Pharmaceuticals' Sales General And Administrative To Revenue is fairly stable compared to the past year. Cash Per Share is likely to rise to 45.71 in 2024, whereas Price To Sales Ratio is likely to drop 10.09 in 2024.

	2021	2022	2023	2024 (projected)
Days Sales Outstanding	54.78	58.94	57.82	58.28
PTB Ratio	5.6	5.32	5.96	7.46

Days Sales Outstanding Ptb Ratio

Vertex Pharmaceuticals fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		0.81	0.18	-0.38	-0.7	-0.52	-0.38	0.81	1.0	-0.51	-0.63	-0.08	-0.49	-0.11	-0.51	0.37	-0.39	-0.32	-0.41	-0.36	-0.52	0.33	0.06	-0.73	-0.31	-0.27
Ptb Ratio	0.81		0.15	-0.58	-0.69	-0.69	-0.11	1.0	0.83	-0.7	-0.79	-0.07	-0.69	-0.01	-0.38	0.15	-0.58	-0.3	-0.55	-0.18	-0.4	0.45	0.15	-0.65	-0.3	-0.24
Days Sales Outstanding	0.18	0.15		0.5	0.33	0.43	-0.22	0.15	0.16	0.43	0.3	-0.81	0.44	0.3	0.31	-0.42	0.5	0.44	0.61	0.39	0.21	0.32	0.09	0.26	0.43	0.04
Book Value Per Share	-0.38	-0.58	0.5		0.71	0.94	-0.05	-0.58	-0.41	0.94	0.58	-0.39	0.94	-0.01	0.47	-0.4	0.99	0.28	0.96	0.13	0.15	-0.12	0.04	0.59	0.27	0.15
Free Cash Flow Yield	-0.7	-0.69	0.33	0.71		0.85	0.31	-0.69	-0.71	0.85	0.75	-0.27	0.81	0.02	0.81	-0.65	0.75	0.48	0.78	0.44	0.43	-0.12	0.04	0.92	0.46	0.21
Operating Cash Flow Per Share	-0.52	-0.69	0.43	0.94	0.85		0.11	-0.69	-0.54	1.0	0.7	-0.37	0.97	-0.03	0.57	-0.38	0.96	0.37	0.93	0.21	0.25	-0.25	0.11	0.72	0.36	0.21
Capex To Depreciation	-0.38	-0.11	-0.22	-0.05	0.31	0.11		-0.11	-0.38	0.08	0.0	-0.17	0.05	0.35	0.2	-0.08	-0.01	0.31	0.06	0.51	0.46	0.08	0.66	0.4	0.3	0.64
Pb Ratio	0.81	1.0	0.15	-0.58	-0.69	-0.69	-0.11		0.83	-0.7	-0.79	-0.07	-0.69	-0.01	-0.38	0.15	-0.58	-0.3	-0.55	-0.18	-0.4	0.45	0.15	-0.65	-0.3	-0.24
Ev To Sales	1.0	0.83	0.16	-0.41	-0.71	-0.54	-0.38	0.83		-0.54	-0.65	-0.07	-0.51	-0.1	-0.51	0.36	-0.42	-0.33	-0.43	-0.36	-0.52	0.35	0.05	-0.74	-0.32	-0.27
Free Cash Flow Per Share	-0.51	-0.7	0.43	0.94	0.85	1.0	0.08	-0.7	-0.54		0.71	-0.36	0.97	-0.04	0.56	-0.37	0.96	0.37	0.93	0.19	0.24	-0.26	0.09	0.72	0.35	0.19
Roic	-0.63	-0.79	0.3	0.58	0.75	0.7	0.0	-0.79	-0.65	0.71		-0.28	0.77	0.08	0.47	-0.27	0.57	0.61	0.65	0.43	0.55	-0.35	-0.16	0.77	0.61	0.17
Inventory Turnover	-0.08	-0.07	-0.81	-0.39	-0.27	-0.37	-0.17	-0.07	-0.07	-0.36	-0.28		-0.4	-0.63	-0.19	0.24	-0.39	-0.57	-0.53	-0.58	-0.49	-0.34	-0.49	-0.34	-0.56	-0.44
Net Income Per Share	-0.49	-0.69	0.44	0.94	0.81	0.97	0.05	-0.69	-0.51	0.97	0.77	-0.4		-0.01	0.52	-0.35	0.94	0.39	0.94	0.21	0.26	-0.25	0.09	0.74	0.38	0.22
Days Of Inventory On Hand	-0.11	-0.01	0.3	-0.01	0.02	-0.03	0.35	-0.01	-0.1	-0.04	0.08	-0.63	-0.01		-0.14	-0.14	-0.01	0.31	0.12	0.6	0.52	0.56	0.38	0.14	0.3	0.67
Payables Turnover	-0.51	-0.38	0.31	0.47	0.81	0.57	0.2	-0.38	-0.51	0.56	0.47	-0.19	0.52	-0.14		-0.79	0.48	0.29	0.51	0.28	0.25	-0.02	0.07	0.81	0.26	0.06
Capex To Revenue	0.37	0.15	-0.42	-0.4	-0.65	-0.38	-0.08	0.15	0.36	-0.37	-0.27	0.24	-0.35	-0.14	-0.79		-0.42	-0.11	-0.47	-0.31	-0.16	-0.48	0.11	-0.65	-0.09	0.02
Cash Per Share	-0.39	-0.58	0.5	0.99	0.75	0.96	-0.01	-0.58	-0.42	0.96	0.57	-0.39	0.94	-0.01	0.48	-0.42		0.27	0.96	0.14	0.14	-0.1	0.05	0.61	0.26	0.14
Pocfratio	-0.32	-0.3	0.44	0.28	0.48	0.37	0.31	-0.3	-0.33	0.37	0.61	-0.57	0.39	0.31	0.29	-0.11	0.27		0.48	0.88	0.9	-0.07	0.08	0.51	1.0	0.23
Interest Coverage	-0.41	-0.55	0.61	0.96	0.78	0.93	0.06	-0.55	-0.43	0.93	0.65	-0.53	0.94	0.12	0.51	-0.47	0.96	0.48		0.37	0.34	-0.02	0.06	0.68	0.47	0.19
Capex To Operating Cash Flow	-0.36	-0.18	0.39	0.13	0.44	0.21	0.51	-0.18	-0.36	0.19	0.43	-0.58	0.21	0.6	0.28	-0.31	0.14	0.88	0.37		0.92	0.29	0.18	0.5	0.88	0.42
Pfcf Ratio	-0.52	-0.4	0.21	0.15	0.43	0.25	0.46	-0.4	-0.52	0.24	0.55	-0.49	0.26	0.52	0.25	-0.16	0.14	0.9	0.34	0.92		0.03	0.14	0.54	0.9	0.4
Days Payables Outstanding	0.33	0.45	0.32	-0.12	-0.12	-0.25	0.08	0.45	0.35	-0.26	-0.35	-0.34	-0.25	0.56	-0.02	-0.48	-0.1	-0.07	-0.02	0.29	0.03		0.06	-0.09	-0.09	0.17
Income Quality	0.06	0.15	0.09	0.04	0.04	0.11	0.66	0.15	0.05	0.09	-0.16	-0.49	0.09	0.38	0.07	0.11	0.05	0.08	0.06	0.18	0.14	0.06		0.19	0.08	0.77
Roe	-0.73	-0.65	0.26	0.59	0.92	0.72	0.4	-0.65	-0.74	0.72	0.77	-0.34	0.74	0.14	0.81	-0.65	0.61	0.51	0.68	0.5	0.54	-0.09	0.19		0.49	0.37
Ev To Operating Cash Flow	-0.31	-0.3	0.43	0.27	0.46	0.36	0.3	-0.3	-0.32	0.35	0.61	-0.56	0.38	0.3	0.26	-0.09	0.26	1.0	0.47	0.88	0.9	-0.09	0.08	0.49		0.23
Pe Ratio	-0.27	-0.24	0.04	0.15	0.21	0.21	0.64	-0.24	-0.27	0.19	0.17	-0.44	0.22	0.67	0.06	0.02	0.14	0.23	0.19	0.42	0.4	0.17	0.77	0.37	0.23

Click cells to compare fundamentals

Vertex Pharmaceuticals Account Relationship Matchups

Vertex Pharmaceuticals fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	13.5	9.9	7.47	8.28	10.62	10.09
Ptb Ratio	9.24	7.07	5.6	5.32	5.96	7.46
Days Sales Outstanding	55.55	52.07	54.78	58.94	57.82	58.28
Book Value Per Share	23.7	33.43	39.19	54.33	68.22	71.63
Free Cash Flow Yield	0.0266	0.0487	0.0426	0.0531	0.0313	0.0328
Operating Cash Flow Per Share	6.11	12.52	10.26	16.13	13.73	14.41
Stock Based Compensation To Revenue	0.0866	0.0692	0.0583	0.055	0.0589	0.0559
Capex To Depreciation	0.71	2.37	1.87	1.38	1.43	1.1
Pb Ratio	9.24	7.07	5.6	5.32	5.96	7.46
Ev To Sales	12.89	9.02	6.65	7.17	9.66	9.17
Free Cash Flow Per Share	5.82	11.52	9.35	15.33	12.72	13.36
Roic	0.5	0.17	0.3	0.24	0.19	0.2
Inventory Turnover	3.27	2.62	2.56	2.35	1.71	1.62
Net Income Per Share	4.58	10.44	9.09	12.97	14.05	14.75
Days Of Inventory On Hand	111.62	139.19	142.54	155.62	213.64	110.53
Payables Turnover	6.25	4.75	4.64	3.55	3.46	3.63
Research And Ddevelopement To Revenue	0.42	0.29	0.4	0.28	0.32	0.3
Capex To Revenue	0.0181	0.0419	0.031	0.0229	0.0262	0.0249
Cash Per Share	14.83	25.63	29.2	42.09	43.53	45.71
Pocfratio	35.82	18.88	21.41	17.91	29.64	31.12
Interest Coverage	20.47	49.12	45.24	78.6	97.68	102.56
Capex To Operating Cash Flow	0.0481	0.0799	0.0889	0.0496	0.0731	0.0767
Pfcf Ratio	37.63	20.51	23.5	18.84	31.98	33.58
Days Payables Outstanding	58.38	76.91	78.72	102.68	105.52	161.06
Income Quality	1.33	1.2	1.13	1.24	0.98	0.71
Roe	0.19	0.31	0.23	0.24	0.21	0.22
Ev To Operating Cash Flow	34.2	17.21	19.05	15.5	26.94	28.29
Pe Ratio	47.77	22.65	24.16	22.26	28.97	30.42
Return On Tangible Assets	0.34	0.17	0.26	0.19	0.2	0.18
Ev To Free Cash Flow	35.93	18.71	20.91	16.31	29.06	30.52
Earnings Yield	0.0209	0.0442	0.0414	0.0449	0.0345	0.0362
Net Debt To E B I T D A	(1.62)	(1.65)	(2.14)	(2.24)	(2.08)	(1.97)
Current Ratio	5.17	3.83	5.02	4.81	5.22	3.79
Tangible Book Value Per Share	18.24	28.04	33.75	47.72	60.74	63.78
Receivables Turnover	6.57	7.01	6.66	6.19	6.31	8.77
Graham Number	49.44	88.6	89.52	125.92	146.83	154.17
Shareholders Equity Per Share	23.7	33.43	39.19	54.33	68.22	71.63
Debt To Equity	0.011	0.002213	(0.0365)	0.0412	0.0474	0.045

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Vertex Historical Financial Ratios

About Vertex Financial Ratios Analysis

Vertex Pharmaceuticals Financial Ratios Chart

Book Value Per Share

Free Cash Flow Yield

Invested Capital

Vertex Pharmaceuticals fundamentals Correlations

Vertex Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vertex Pharmaceuticals fundamentals Accounts

Also Currently Popular

Additional Tools for Vertex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Cash Per Share	+ 0.99	Book Value Per Share
Net Income Per Share	+ 0.97	Operating Cash Flow Per Share

Inventory Turnover	- 0.81	Days Sales Outstanding
Capex To Revenue	- 0.79	Payables Turnover
Roic	- 0.79	Pb Ratio
Roic	- 0.79	Ptb Ratio
Roe	- 0.74	Ev To Sales
Roe	- 0.73	Price To Sales Ratio